This article was originally published in Start Up
Executive SummaryCoroNovative BV is wagering that company co-founder Albert Osterhaus, PhD--who has a worldwide reputation as an expert on viruses--and the team assembling around him will make a habit of identifying new pathogens, and so provide the organization with intellectual property supportive of novel vaccines, diagnostics and treatments.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.